Mpa Gyn (Medroxyprogesterone Acetate)

Medroxyprogesterone acetate, the active ingredient in Mpa Gyn, is a progestogen presented as an oral formulation for oral use. It is employed in gynecological hormone therapy to manage menstrual disorders, endometriosis, secondary amenorrhea, hormone replacement therapy and contraception in women of reproductive age.

GNH USA supplies Mpa Gyn as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mpa Gyn, a synthetic progestogen, is used in several gynecological conditions that involve hormonal regulation.

- Menstrual disorders: helps regularize cycle length and reduce abnormal uterine bleeding. - Endometriosis: suppresses ectopic endometrial tissue growth and alleviates pelvic pain. - Secondary amenorrhea: induces withdrawal bleeding by stimulating endometrial shedding. - Hormone replacement therapy: provides progestogenic support in post‑menopausal regimens. - Contraception: prevents ovulation and creates an endometrial environment unsuitable for implantation.

Adverse reactions may occur with any hormonal therapy and should be monitored.

Common Side Effects: - Weight gain: mild increase in body weight. - Headache: transient tension‑type headaches. - Nausea: occasional stomach upset. - Breast tenderness: mild discomfort or swelling. - Mood changes: irritability or mild depressive symptoms.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Liver dysfunction: jaundice or elevated liver enzymes. - Hyperglycemia: elevated blood glucose in susceptible individuals.

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly.

- Contraindications: avoid in patients with known hypersensitivity to medroxyprogesterone acetate. - Pregnancy: not recommended during pregnancy; assess risk‑benefit if exposure occurs. - Breastfeeding: use with caution; potential excretion in milk. - Cardiovascular risk: assess history of thrombosis or cardiovascular disease. - Liver disease: monitor hepatic function in patients with pre‑existing liver conditions. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Medroxyprogesterone acetate may alter the efficacy of several concomitant medicines.

Major Interactions (Avoid): - Anticoagulants: may increase bleeding risk; monitor INR or clotting parameters. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): can reduce plasma levels and effectiveness.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: progestogens can affect glucose control; adjust monitoring. - Antihypertensives: possible fluid retention may influence blood pressure. - Other hormonal agents: combined use may increase risk of thromboembolism.